Rekah Pharmaceutical Industry Ltd
TASE:REKA
Intrinsic Value
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. [ Read More ]
The intrinsic value of one REKA stock under the Base Case scenario is 1 983.2 ILS. Compared to the current market price of 1 356 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 32%.
Valuation Backtest
Rekah Pharmaceutical Industry Ltd
Run backtest to discover the historical profit from buying and selling REKA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Rekah Pharmaceutical Industry Ltd
Current Assets | 237.3m |
Cash & Short-Term Investments | 14m |
Receivables | 126.1m |
Other Current Assets | 97.1m |
Non-Current Assets | 233.7m |
Long-Term Investments | 1.3m |
PP&E | 153.7m |
Intangibles | 66m |
Other Non-Current Assets | 12.7m |
Current Liabilities | 140.9m |
Accounts Payable | 93m |
Short-Term Debt | 24.2m |
Other Current Liabilities | 23.7m |
Non-Current Liabilities | 173.7m |
Long-Term Debt | 138.5m |
Other Non-Current Liabilities | 35.2m |
Earnings Waterfall
Rekah Pharmaceutical Industry Ltd
Revenue
|
315.3m
ILS
|
Cost of Revenue
|
-235.6m
ILS
|
Gross Profit
|
79.7m
ILS
|
Operating Expenses
|
-74.1m
ILS
|
Operating Income
|
5.6m
ILS
|
Other Expenses
|
-14m
ILS
|
Net Income
|
-8.4m
ILS
|
Free Cash Flow Analysis
Rekah Pharmaceutical Industry Ltd
REKA Profitability Score
Profitability Due Diligence
Rekah Pharmaceutical Industry Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Rekah Pharmaceutical Industry Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
REKA Solvency Score
Solvency Due Diligence
Rekah Pharmaceutical Industry Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Rekah Pharmaceutical Industry Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REKA Price Targets Summary
Rekah Pharmaceutical Industry Ltd
Shareholder Return
REKA Price
Rekah Pharmaceutical Industry Ltd
Average Annual Return | -7.84% |
Standard Deviation of Annual Returns | 28.76% |
Max Drawdown | -55% |
Market Capitalization | 160.5m ILS |
Shares Outstanding | 118 385 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Contact
IPO
Employees
Officers
The intrinsic value of one REKA stock under the Base Case scenario is 1 983.2 ILS.
Compared to the current market price of 1 356 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 32%.